FDA Expands Approval of Fulvestrant for Advanced Breast Cancer

FDA has expanded its approval of fulvestrant (Faslodex®) as a standalone treatment for postmenopausal women with advanced HR-positive, HER2-negative breast cancer who have not previously undergone endocrine therapy.

Cancer Currents: An NCI Cancer Research Blog